

**UPVG0009-100  
PATENT APPLICATION****SERIAL NO.: 09/680,690  
FILED: OCTOBER 6, 2000****Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 11 and 32, and amend claims 1, 12, 13 and 33 as follows.

1. (Currently Amended) A method of introducing a compound into a cell that expresses CD80 and/or CD86 costimulatory molecules, said method comprising contacting the cell with a non-cellular particle that comprises the compound and a ligand comprising CD28 or a portion thereof including the extracellular region of CD28; wherein said compound is a nucleic acid molecule, and said non-cellular particle is selected from the group consisting of: a liposome and a cationic amphiphile/DNA complex.
2. previously canceled
3. (Previously Presented) The method of claim 1 wherein the compound is DNA.
4. (Previously Amended) The method of claim 1 wherein the compound is DNA that comprises a nucleotide sequence that encodes a protein operably linked to regulatory elements functional in the cell.
5. (Previously Amended) The method of claim 1 wherein the cell that expresses costimulatory molecules is a dendritic cell or a macrophage.
6. (Previously Amended) The method of claim 1 wherein the compound is DNA that comprises a nucleotide sequence that encodes an non-immunogenic protein operably linked to regulatory elements functional in the cell.

UPVG0009-100  
PATENT APPLICATION

SERIAL NO.: 09/680,690  
FILED: OCTOBER 6, 2000

7. previously canceled
8. (Previously Amended) The method of claim 1 wherein the ligand is a fusion protein that includes CD28 or a portion thereof including the extracellular region of CD28 and a viral portion.
9. previously canceled
10. (Previously Amended) The method of claim 1 wherein the cell that expresses CD80 and/or CD86 costimulatory molecules is a dendritic cell.
11. canceled
12. (Currently Amended) A method of introducing a compound into a cell that expresses CD80 and/or CD86 costimulatory molecules comprising contacting the cell with a particle that comprises the compound and a fusion protein, the fusion protein comprising the extracellular region of CD28 and the cytoplasmic and transmembrane regions of HIV gp41; wherein said compound is a nucleic acid molecule, and said non-cellular particle is selected from the group consisting of: a protein complex that comprises two or more protein molecules and a nucleic acid molecule; a liposome; and a cationic amphiphile/DNA complex.
13. (Currently Amended) A method of delivering a therapeutic protein to an individual comprising the step of administering to tissue of said individual at a site on said individual's body, a particle that comprises a nucleic acid molecule that encodes a therapeutic protein and a ligand comprising CD28 or a portion thereof including the extracellular region of CD28; wherein said particle is selected from the group consisting of: a protein complex that comprises two or more protein molecules and a nucleic acid molecule; a liposome; and a cationic amphiphile/DNA complex.
- 14-31 previously canceled

UPVG0009-100  
PATENT APPLICATION

SERIAL NO.: 09/680,690  
FILED: OCTOBER 6, 2000

32. canceled
33. (Currently Amended) The method of claim 10 wherein the ligand is a fusion protein that includes CD28 or a portion thereof including the extracellular region of CD28 and a viral protein portion that of the fusion protein comprises HIV-1 gp41 or a portion thereof.
34. (Previously Presented) The method of claim 33 wherein said viral protein portion of the fusion protein comprises the transmembrane and cytoplasmic regions of HIV gp41.
35. previously canceled
36. previously canceled
37. (Previously Presented) The method of claim 34 wherein the compound is DNA.
38. (Previously Presented) The method of claim 34 wherein the compound is DNA that comprises a nucleotide sequence that encodes a protein operably linked to regulatory elements functional in the cell.
39. (Previously Presented) The method of claim 34 wherein the compound is DNA that comprises a nucleotide sequence that encodes an immunogenic protein operably linked to regulatory elements functional in the cell.
40. (Previously Presented) The method of claim 34 wherein the compound is DNA that comprises a nucleotide sequence that encodes a non-immunogenic protein operable linked to regulatory elements functional in the cell.
41. (Previously Presented) The method of claim 34 wherein the cell that expresses CD80 and/or CD86 costimulatory molecules is a dendritic cell.

**UPVG0009-100  
PATENT APPLICATION**

**SERIAL NO.: 09/680,690  
FILED: OCTOBER 6, 2000**

42. (Previously Presented) The method of claim 34 wherein the particle is a viral particle, a complex that comprises two or more protein molecules and a nucleic acid molecule, a liposome or a cationic amphiphile/DNA complex.